PHARMACY Section 9. Overview. Preferred Drug List. Additions and Exceptions to the Preferred Drug List

Similar documents
Coventry Health Care of Georgia, Inc.

Pharmaceutical Management Medicaid 2019

FlexRx 6-Tier. SM Pharmacy Benefit Guide

Pharmacy benefit guide

PHARMACY BENEFITS MANAGER

Issues for Part D Compliance

Getting started with Prime

News & Views. Antipsychotics on Maryland Medicaid PDL and Coverage of a 30-day Emergency Supply of Atypical Antipsychotics

$250 (Deductible does not apply to Tier 1 and Tier 2) $500 (Deductible does not apply to Tier 1 and Tier 2)

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

PBMs: Impact on Cost and Quality of Pharmaceutical Care in the U.S.

Get the most from your prescription plan

Coverage Period: 01/01/ /31/2018 Coverage for: Individual and/or Family Plan: Healthy Rewards HSA

Alabama Medicaid Pharmacy Override

Coverage Period: Coverage for: Plans: This is only a summary of your GatorCare pharmacy benefits. Coinsurance: you your Dependent Copayment: you

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

2016 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

Get the most from your prescription plan

This document is to help guide the use of the provided GRH IV Iron Sucrose package. The documents included in the IV Iron Sucrose Package are:

2018 Travelers Prescription Drug Plan High Deductible + HSA Plan

See Important Reminder at the end of this policy for important regulatory and legal information.

Your Prescription Card. Your guide for savings.

A&M Care Prescription Drug Program Express Scripts Holding Company. All Rights Reserved.

Public Health Service Breakout Session 1

Practice Direction Refill History Recording System

General Providers. Tamper-Resistant Prescription Requirements

Furthermore, medications dispensed by physicians often cost more for the payer than the same medication dispensed by a retail pharmacy.

1, 2014 PHARMACY BENEFIT

Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.

Medicare Part D Prescription Opioid Policies for 2019 Information for Pharmacists

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Your Prescription Card. Your guide for savings.

Prescription Medication Guidelines for Medical Providers in CorVel s CorCare and Care IQ Networks

Medication Therapy Management program

Section I. Short-acting opioid Prior Authorization Criteria

An Overview of One Formulary Making Decision Process

See reverse side for important facts about how to save on your prescriptions.

April 21, 2010 DURB Meeting Summary

CYTOKINE AND CAM ANTAGONIST UTILIZATION IN MISSISSIPPI MEDICAID

A Family Medicine Cabinet

The Un-Special World of Specialty Medications

Pharmacy Audit Recovery Guidelines

Schedule of Benefits Summary Group Name: Nebraska Bankers Association VEBA Effective Date: January 01, 2018

Prescription Drug Importation: Can it Help America's Seniors? Safety of Imported Medications: I-SaveRx Case Study

ProviderNews FEBRUARY

See Important Reminder at the end of this policy for important regulatory and legal information.

HUSKY Health Benefits and Prior Authorization Requirements Grid* Behavioral Health Partnership Effective: January 1, 2012

Medicare Parts B/D Coverage Issues

See Important Reminder at the end of this policy for important regulatory and legal information.

Curbing Prescription Drug Abuse in Medicaid

CALIFORNIA. When I Fill a Prescription, How Much Medication Do I Receive? What Is My Schedule of Benefits? How Do I Use My Prescription Drug Benefit?

Overview Purpose Complete the Qsymia Pharmacy Certification in 3 easy steps:

Overview. Purpose. Qsymia (phentermine and topiramate extended-release) capsules CIV Pharmacy Training Program

RE: CMS-4130-P (Medicare Program; Policy and Technical Changes to the Medicare Prescription Drug Benefit)

Your Prescription Card. Your guide for savings.

9/25/15. Pharmacy Quality Measures: Financial Support. Learning Objectives. Speaker Disclosure. Access to Preferred Networks and Clinical Performance

Background. CMS finalized new policies for Medicare drug plans to follow starting on January 1,2019.

New Medicare Part D Prescription Opioid Policies for 2019 Information for Prescribers

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19

Health TALK. Take charge. Health4Me TM. Prepare to see your provider.

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

New Mexico Retiree Health Care Authority Medicare Part D Prescription Drug Program Express Scripts Holding Company. All Rights Reserved.

See Important Reminder at the end of this policy for important regulatory and legal information.

View/Enter Patient Record. 3.1 CP-UC1-PS1 Refill Prescription (CASH)

Schedule of Benefits Summary Group Name: Nebraska Bankers Association VEBA Effective Date: January 01, 2018

Schedule of Benefits Summary Group Name: Nebraska Bankers Association VEBA Effective Date: January 01, 2018

See Important Reminder at the end of this policy for important regulatory and legal information.

FLOWTUSS (hydrocodone bitartrate and guaifenesin) oral solution OBREDON (hydrocodone bitartrate and guaifenesin) oral solution

RECEIVING YOUR PERMANENT

Maryland Department of Health and Mental Hygiene /Office of Systems, Operations and Pharmacy. Date Prescription will Start Denying at the

See Important Reminder at the end of this policy for important regulatory and legal information.

BLOOD GLUCOSE METER TEST STRIP STEP THERAPY CRITERIA

How to Design a Tobacco Cessation Insurance Benefit

PHARMACY BENEFITS MANAGER SELECTION FAQ FOR PRODUCERS

Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for Fentanyl Transdermal Patch

See Important Reminder at the end of this policy for important regulatory and legal information.

Using CURES to combat prescription drug abuse/misuse

STEP THERAPY IN MEDICARE PART D

Annual Eye Exams Part of Diabetic Care

Florida MEDS-AD Waiver

Your Guide to NOCTIVA

ENSURING EXCELLENCE IN PRESCRIBING FOR OLDER ADULTS

Medicare Part D Overutilization Monitoring System

Principal Benefits for Kaiser Permanente Traditional HMO (1/1/16 12/31/16)

Health TALK. Flu fighters. Arm your family against the flu. The Key to a good life is a great plan

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Nova Scotia Drug Information System

NATPARA (parathyroid hormone) for injection Risk Evaluation and Mitigation Strategy (REMS) Program

PHARMACY COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/16/17 SECTION: DRUGS LAST REVIEW DATE: 11/16/17 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Clinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18

Navigating Pain Management during the Opioid Epidemic: Focus Group Findings

Understanding the Value of Generic Drugs

Idaho DUR Board Meeting Minutes

See Important Reminder at the end of this policy for important regulatory and legal information.

NAVIGATING THE HEALTH CARE SYSTEM. Floyd Shewmake, MD Senior Medical Director Coventry Health Care

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Texas Vendor Drug Program Specialty Drug List Process. February 2019

Transcription:

Overview The management of outpatient prescription drugs is an integral part of the medical management program to improve the health and well-being of our members. Prescriber and member involvement is critical to the success of the pharmacy program. To help your patients get the most out of their pharmacy benefit, please be cognizant of the following guidelines when prescribing: Follow national standards of care guidelines for treating conditions i.e., NIH Asthma guideline, JNC VII Hypertension guidelines; Prescribe drugs from the Preferred Drug List (PDL); Prescribe generic drugs when therapeutic equivalent drugs are available; and Evaluate medication profiles for appropriateness and duplication of therapy. Preferred Drug List The PDL is a standardized prescribing reference and clinical guide of prescription drug products selected by the Pharmaceutical and Therapeutics Committee (P&T Committee). The P&T Committee selection of drugs is based on the efficacy, safety, side effects, pharmacokinetics, clinical literature and cost-effectiveness profile. The medications listed on the PDL are organized by therapeutic class, product name, strength, form and coverage details (quantity limits, age limitations, prior authorizations and step therapies). Ohana Health Plan will inform providers of any changes and updates to the PDL. The Ohana PDL may be viewed and downloaded at www.ohanahealthplan.com. Additions and Exceptions to the Preferred Drug List To request consideration for inclusion of a drug to the Plan s PDL, please write or fax the Plan explaining the medical justification. Requests should be addressed to: Hawai i Provider Manual Medicaid October 2011 Page 1 of 5

Ohana Health Plan Clinical Pharmacy Dept. Director of Clinical Pharmacy Pharmacy & Therapeutics Committee P.O. Box 31401 Tampa, FL 33631-3401 Drug Evaluation Review Process The goal of the Drug Evaluation Review (DER) program is to ensure that medication regimens that are high-risk, have a high potential for misuse or have narrow therapeutic indices are used appropriately and according to FDA approved indications. The DER process is required for: Duplication of therapy Prescriptions that exceed the FDA daily or monthly quantity limit Most self-injectable and infusion medications Drugs not listed on the PDL Drugs listed on the PDL with a Prior Authorization Brand name drugs when a generic exists Drugs that have a step edit and the first line therapy is inappropriate Drugs that have an age edit Obtaining a Drug Evaluation Review Complete a DER form which is located in the Forms section of the Provider Manual and on our Web site at www.ohanahealthplan.com. Fax the form to the Pharmacy department using the fax number provided on the Quick Reference Guide. Our standard is to respond to requests within 72 hours. Please provide pertinent medical history and information when submitting a DER form for medical exception. Hawai i Provider Manual Medicaid October 2011 Page 2 of 5

If the DER meets the approved P&T Committee protocols and guidelines, the provider and/or pharmacy will be notified of the DER approval. If the DER is not a candidate for approval based on approved P&T protocols and guidelines, it is initially reviewed by a clinical pharmacist and secondly reviewed by the medical director for final determination. For those requests that are not approved, a follow-up Drug Utilization Review (DUR) form is faxed to the provider stating why the DER was not approved and listing the preferred drugs that are available as alternatives. To request an appeal of a DER decision, mail or fax your request to the Appeals and Grievances department. Refer to the Quick Reference Guide for the address and fax number. The request will follow the appeals process described in the Appeals and Grievances section of this manual. Emergency Supply Ohana Health Plan will provide an emergency supply of medication until a DER (prior authorization) decision has been made. Generic Medications Generic drugs are equally effective and generally less costly than brand-name medication. Their use can contribute to cost-effective therapy and must be dispensed by the pharmacist when a therapeutically equivalent to a brand-name drug is available. An exception to the mandatory generic policy when a therapeutically equivalent drug is available requires medical justification. A Drug Evaluation Review (DER) form should be completed when requesting an exception. Injectable Infusion Services Select self-injectable drugs are covered under the outpatient pharmacy benefit. Most self-injectable products and all infusion drug requests require a DER and are supplied by contracted retail pharmacies and infusion vendors. Specialty drugs require a DER and are not Hawai i Provider Manual Medicaid October 2011 Page 3 of 5

available through the retail pharmacy network. To obtain authorization, the provider must submit the appropriate DER form to the Ohana Pharmacy Department via fax. The Pharmacy Department will respond to all requests within 72 hours and, if authorized, will coordinate delivery of the product. Coverage Limitations The following is a list of non-covered (excluded) drugs and/or categories: Drugs used for anorexia or weight gain; Drugs used to promote fertility; Drugs for the treatment of erectile dysfunction; Drugs used for cosmetic purposes or hair growth; Vitamins, except for prenatal vitamins and vitamins listed on the PDL; Cough and cold combination medications for members age 21 and older; Investigational or experimental drugs; and DESI drugs or drugs that may have been determined to be identical, similar or related. Duplicate therapy and early refills will require a DER, if medically necessary. Step-Therapy Programs Step-therapy programs are developed by the P&T Committee. These programs are designed to provide members with clinically sound, cost-effective drug treatment options. Step-therapy programs encourage the use of select therapies before alternative therapies are prescribed. These programs undergo an extensive review of clinical literature, manufacturer product information and Hawai i Provider Manual Medicaid October 2011 Page 4 of 5

consultation with medical professionals to ensure a clinically comprehensive program. Over-the-Counter Medications Some over-the-counter (OTC) medications are available to the member with a prescription. Refer to the PDL for a complete list of available OTC drugs. Member Co-payments There are no prescription co-pay requirements. Pharmacy Network Improvement Program The pharmacy network improvement program is designed to provide physicians with quarterly utilization reports to identify over and under utilization of pharmaceutical products. The reports will also identify opportunities for optimizing best practices guidelines and cost-effective therapeutic options. Hawai i Provider Manual Medicaid October 2011 Page 5 of 5